Skip to content

Evaluation of Clinical Efficacy of Acupuncture Point Embedding Intervention in Chronic Persistent Asthma

The efficacy and safety of implantable thread therapy for chronic persistent allergic asthma: a randomized controlled trial

Status
Recruiting
Phases
Unknown
Study type
Interventional
Source
ITMCTR
Registry ID
ITMCTR2026001590
Enrollment
Unknown
Registered
2026-06-26
Start date
2025-12-01
Completion date
Unknown
Last updated
2026-08-03

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Allergic asthma

Interventions

Thread Implantation Group:Thread Implantation
Sham group:Wireless in-body implantation

Sponsors

Shanxi Province Acupuncture Hospital
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 65 Years

Inclusion criteria

Inclusion criteria: (1) Presenting with clinical symptoms such as wheezing, shortness of breath, chest tightness, and coughing; (2) Meeting the diagnostic criteria for mild to moderate asthma according to the classification standards; (3) Of any gender, aged 18 to 65 years, with good mental status, able to cooperate with treatment and examinations, and capable of objectively and accurately expressing the treatment outcomes; (4) Having not participated in any other clinical study within the past month; (5) Willing to cooperate voluntarily and having signed the informed consent form.

Exclusion criteria

Exclusion criteria: (1) Patients with mild or severe acute exacerbations of allergic asthma, as well as those in the chronic persistent phase; (2) Patients with a confirmed history of respiratory system diseases affecting lung function, including pneumonia, pulmonary tuberculosis, lung abscess, and other pulmonary infectious diseases; bronchiectasis, chronic bronchitis, chronic obstructive pulmonary disease (COPD), and other airway diseases; (3) Patients with incomplete case records; (4) Patients with mental disorders; (5) Patients with severe cardiovascular, cerebrovascular, immune system diseases, or malignant tumors; (6) Patients who have participated in another clinical trial or received treatment for respiratory system diseases within the past 12 weeks; (7) Patients with contagious skin diseases or skin damage in the treatment area; (8) Pregnant women, breastfeeding women, or those suspected of being pregnant; (9) Patients with a fear of needles or a history of fainting due to needles.

Design outcomes

Primary

MeasureTime frame
Asthma Control Questionnaire;

Secondary

MeasureTime frame
SF-36;PFT;

Countries

China

Contacts

Public ContactJi Laixi

Shanxi University of Traditional Chinese Medicine

tyjilaixi@126.com13509714277

Outcome results

None listed

Source: ITMCTR (via WHO ICTRP) · Data processed: Aug 10, 2026